Sepsis May Leave Tissues Primed for Cancer, Review Argues

Every year, millions of people survive sepsis, the life-threatening dysregulation of the body’s response to infection, only to face a shadowy aftermath that medicine is only beginning to map. A new review published in the Journal of Translational Medicine proposes a provocative idea: the severe systemic inflammation that defines sepsis may remodel distant tissues in ways that strikingly resemble the so-called pre-metastatic niche, the biological soil that circulating cancer cells exploit when they seed new tumors. The authors, led by Juan S. Izquierdo-Condoy and Esteban Ortiz-Prado of Universidad de Las Américas in Ecuador, argue that sepsis could serve as a clinically observable model of post-inflammatory tissue priming, offering researchers a window into how organs become permissive to abnormal cellular colonization long before any malignant cell arrives.

The classical pre-metastatic niche paradigm, developed over the past two decades, holds that primary tumors actively prepare distant sites for colonization by releasing soluble factors and extracellular vesicles that travel through the bloodstream and reprogram future metastatic destinations. Bone marrow–derived cells are recruited, blood vessels become leaky and adhesive, immune defenses are suppressed, and the extracellular matrix is degraded and reorganized. What this paradigm does not explain, the review’s authors note, is whether catastrophic systemic inflammation by itself, without any tumor present, can generate similar tissue states. Their answer, assembled from a synthesis of immunological, vascular, and matrix biology, is that it plausibly can, through what they term an Immuno–Vascular–Matrix Triad.

The first arm of the triad is immunological. Sepsis unleashes a storm of damage-associated molecular patterns, including high-mobility group box 1, mitochondrial DNA, and adenosine triphosphate, which flood the circulation as injured cells rupture. These alarmins engage Toll-like receptors, most notably TLR4, on immune and stromal cells, igniting signaling cascades that sustain inflammation well beyond the initial insult. In the acute phase, neutrophils respond with explosive production of neutrophil extracellular traps, web-like lattices of DNA and antimicrobial proteins that normally help contain pathogens. When this NETosis becomes dysregulated, it feeds immunothrombosis, promoting platelet activation and diffuse microthrombosis that choke off capillary beds and create focal pockets of hypoxia throughout the body’s tissues.

Hypoxia is not a passive consequence in this framework but an active remodeling signal. Oxygen-starved regions stabilize hypoxia-inducible factor-1α, a transcription factor that reprograms cellular metabolism and drives angiogenic and pro-adhesive gene expression, echoing the low-oxygen conditions that characterize developing metastatic niches. Meanwhile, the immune system enters a prolonged state of dysfunction that the authors describe as immunodisruption. Lymphopenia, the depletion of circulating lymphocytes, can persist long after a patient has technically recovered. Surviving T cells become exhausted through checkpoint pathways such as PD-1 and CTLA-4, the same molecular brakes that tumors exploit to escape immune attack. Regulatory T cells expand, dampening inflammatory responses but also blunting anti-tumor surveillance, and monocytes lose expression of human leukocyte antigen-DR, impairing their ability to present antigens and coordinate adaptive immunity.

The second arm of the triad concerns the vasculature. Sepsis inflicts direct injury on the endothelium, the single-cell lining of blood vessels that normally acts as a selective barrier and a gatekeeper for immune cell traffic. Glycocalyx degradation, endothelial activation, and increased vascular permeability allow plasma proteins and cells to leak into surrounding tissue. In the pre-metastatic niche literature, vascular leakiness and endothelial hyperadhesiveness are hallmark features that facilitate the extravasation of circulating tumor cells. The review argues that post-sepsis endothelium displays a functionally analogous phenotype: vessels that are more permeable, more adhesive to circulating myeloid cells, and less selective about what crosses them. Persistent recruitment of myeloid cells into tissues, a process sustained by altered chemokine signaling, mirrors the way tumors co-opt bone marrow–derived cells to prepare metastatic sites.

The third arm involves the extracellular matrix, the fibrous scaffold that gives tissues their architecture and mechanical properties. During sepsis, mesenchymal stromal cells and inflammatory extracellular vesicles drive the release of matrix metalloproteinases, enzymes that cleave collagen, laminin, and fibronectin. The result is a matrix that is mechanically unstable, abnormally permeable, and richly pro-adhesive, presenting cryptic binding sites and altered stiffness cues to any cell that encounters it. In established cancer biology, matrix remodeling of this kind lowers the barriers to tumor cell invasion and supports the survival of newly arrived malignant cells. The review proposes that a post-sepsis matrix, transiently or perhaps chronically remodeled, could create comparable conditions of systemic permissiveness, lowering tissue resistance to aberrant cellular persistence of many kinds.

What makes the framework scientifically interesting is its convergence logic. None of the individual components is novel; immunothrombosis, endothelial activation, lymphopenia, and matrix degradation are each well documented in sepsis research. The review’s contribution is to assemble them into a coordinated model and to point out that their combined output, endothelial hyperadhesiveness, reduced immune selectivity, persistent myeloid recruitment, and increased tissue susceptibility, is precisely the functional signature that tumor biologists use to define a pre-metastatic niche. In this reading, sepsis does not cause cancer directly, and the authors are careful to frame the triad as a host-conditioned state of biological plausibility rather than an oncogenic event. The claim is about vulnerability and permissiveness, not causation, and it is explicitly presented as a generator of testable hypotheses rather than a settled conclusion.

That framing matters, because the epidemiological question of whether sepsis survivors face elevated cancer risk remains open and contested in the broader literature. What the review offers is a mechanistic roadmap for investigating that question rigorously. If post-sepsis patients carry measurable, persistent signatures of niche-like priming, elevated circulating markers of endothelial activation, sustained shifts in lymphocyte subsets, altered matrix turnover products, then longitudinal cohort studies could track whether these signatures predict subsequent malignancy diagnoses. Such biomarkers would also serve a second purpose: stratifying the growing population of sepsis survivors, whose numbers have grown as intensive care keeps more patients alive, by their biological risk profile rather than by clinical appearance alone.

The clinical implications extend to post-sepsis recovery monitoring more broadly. Post-sepsis syndrome, encompassing cognitive decline, physical disability, and renewed susceptibility to infection, is increasingly recognized as a major public health burden, yet follow-up care for survivors remains fragmentary in most health systems. If the Immuno–Vascular–Matrix Triad proves measurable in routine clinical practice, it could anchor a new category of surveillance: not merely checking whether organs have recovered their function, but assessing whether tissues have returned to a state of immunological and structural integrity. Interventions that restore immune competence, protect the endothelium, or modulate matrix remodeling could then be evaluated for their ability to reverse primed tissue states before they translate into disease.

The authors are candid about the limits of their synthesis. It is a review, built on mechanistic reasoning across literatures that rarely speak to one another, and it does not present direct experimental evidence that sepsis-primed tissues accept circulating tumor cells more readily. Animal models that induce sepsis and then challenge animals with tumor cell lines would be an obvious next step, as would careful analysis of cancer incidence in large sepsis registries with adequate follow-up and control for confounders such as smoking, comorbidities, and post-sepsis surveillance bias, since survivors undergo more medical attention and thus more diagnosis. Even so, the conceptual payoff is considerable: it reframes sepsis not only as an acute crisis to survive but as a systemic remodeling event whose biological echoes may persist, and it hands researchers a concrete, three-part framework for testing whether the body’s fiercest inflammatory storm can quietly prepare the ground for its next great challenge.

Subject of Research: Post-sepsis tissue remodeling as a mimic of the pre-metastatic niche through immune, vascular, and extracellular matrix alterations

Article Title: Sepsis as a pre-metastatic niche mimic: post-sepsis microenvironmental priming through an Immuno–Vascular–Matrix Triad

Article References: Izquierdo-Condoy, J. S., Saavedra-Torres, J. S., Nati-Castillo, H. A., Gil, J. C., García-Aguilera, M. F., Alexander-León, H. A., Lara Puello, I. M., Vargas Saltos, M., & Ortiz-Prado, E. (2026). Sepsis as a pre-metastatic niche mimic: post-sepsis microenvironmental priming through an Immuno–Vascular–Matrix Triad. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08951-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08951-z

Keywords: sepsis, pre-metastatic niche, metastasis, immunothrombosis, immunodisruption, extracellular matrix remodeling, endothelial dysfunction, HMGB1, neutrophil extracellular traps, HIF-1α, matrix metalloproteinases, cancer microenvironment